Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41428 | 0.78 | CA1 (0.55) | SMN1; SMN2CA1RAB9ACA12CA2 | |
| SCHEMBL26180560 | 0.69 | LMNA (0.33) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL381097 | 0.67 | CA1 (0.56) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL667530 | 0.67 | CA1 (0.47) | SMN1; SMN2LMNAHTTCA1NPC1 | |
| SCHEMBL41865 | 0.65 | — | — | |
| SCHEMBL475392 | 0.65 | — | — | |
| SCHEMBL244840 | 0.65 | — | — | |
| SCHEMBL25927048 | 0.64 | LMNA (0.33) | SMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL24381733 | 0.63 | — | — | |
| SCHEMBL4077299 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2939675-B1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-12-11 | — | — | US | disclosed |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20150329540-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2939675-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | Shin Nippon Biomedical Laboratories, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2448921-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1505063-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1221443-B1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| US-6699880-B1 | STIMULATE MUSCARINIC ACETYLCHOLINE RECEPTORS M4, ANALGESICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-1221443-A1 | SUBSTITUTED IMIDAZOLIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | SMN1; SMN2 2582/4885LMNA 3895/4885HTT 2278/4885 |
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | SMN1; SMN2 1070/4885LMNA 4373/4885HTT 3202/4885 |
| US-10149840-B2 | OCT3 activity inhibitor containing imidazopyridine derivative as active component, and OCT3 detection agent | SLCO1B3, SLC22A8, SLCO4C1 | SMN1; SMN2 4173/4885LMNA 3610/4885HTT 3516/4885 |
| US-20180000797-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | SMN1; SMN2 4173/4885LMNA 3610/4885HTT 3516/4885 |
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | SMN1; SMN2 2200/4885LMNA 2385/4885HTT 797/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | SMN1; SMN2 1869/4885LMNA 1460/4885HTT 1228/4885 |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | IDO1, NAT1, IDO2 | SMN1; SMN2 4231/4885LMNA 2834/4885HTT 72/4885 |
| US-20150329540-A1 | OCT3 ACTIVITY INHIBITOR CONTAINING IMIDAZOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT, AND OCT3 DETECTION AGENT | SLCO1B3, SLC22A8, SLCO4C1 | SMN1; SMN2 4299/4885LMNA 3677/4885HTT 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.